Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
H1N1 (Swine Flu) and You
Life Expectancy With HIV Increases Dramatically
HIV Associated With Marked Declines in Lung Function
Is Marijuana as Effective as OTC and Prescription Drugs?
HPV Vaccine Is Active in MSM
MACS Turns 25: The Influential HIV Study Continues
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

May 28, 2008

Monitoring Board Finds HIV Combo Inferior

A monitoring board for an international trial comparing three antiretroviral (ARV) regimens has found that Reyataz (atazanavir) combined with Emtriva (emtricitabine) and Videx-EC (didanosine) is inferior to the others studied in terms of viral control. The board has ordered that patients receiving the once-daily Reyataz-based regimen be switched to another drug combination in consultation with their health care provider.

All clinical studies have a Data and Safety Monitoring Board (DSMB) that regularly evaluates the accumulating data to ensure the safety of the participants. In this case, the DSMB was evaluating data from AIDS Clinical Trials Group (ACTG) study 5175, comparing the Reyataz-based regimen to two Sustiva (efavirenz)-based regimens that included either Combivir (zidovudine plus lamivudine) or Truvada (emtricitabine and tenofovir).

According to the DSMB, of the 1,500-patient ACTG trial, people on the Reyataz-based regimen were significantly less likely to have control of their HIV than people taking the other two regimens. For this reason, all people on the problem regimen have now been alerted to the fact and will be switched to an alternative regimen.

In the United States and other industrialized nations, Reyataz is frequently used with low-dose Norvir (ritonavir) to boost its effectiveness.

Search: DSMB, ACTG, 5175, Reyataz, atazanavir, Emtriva, emtricitabine, Videx, didanosine, Combivir, zidovudine, lamivudine, Truvada, tenofovir, Norvir, ritonavir


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

Marcos, SP, Brazil, 2008-05-30 07:58:19
Hi Michael, A relationship with your doctor based on confidence should exist. If you have doubts about it, I strongly advice you to try other doctor? I did it and didn´t regret so far.

Michael, Plano, 2008-05-29 15:56:23
I found the article on Reyataz combo therapy troublesome. I just started the norvir boosted regimen with Truvada and have felt ill and tired ever since. My doctor gave me no other options and am concerned especially due to history of heart disease in the family as well as my own history. He's suppose to be the best in Dallas but I can't seem to get through to him that I'm not happy about this cocktail and he chalks my fatigue up to low tcells, even though I felt great before. Any advice?

comments 1 - 2 (of 2 total)    


[Go to top]

Get Started
Get Answers
I'm HIV positive. What's next?
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]